Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.

PropertyValue
has major subject area list Antineoplastic Agents; Fallopian Tube Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines
information resource reference Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol. 2015 Jul; 138(1):55-61.
label A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.

Search Criteria
  • Fallopian Tube Cancer